Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2Completed 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 549Neoplasms 384Carcinoma, Non-Small-Cell Lung 319Colorectal Neoplasms 290Lung Neoplasms 239Prostatic Neoplasms 219Carcinoma, Hepatocellular 212Stomach Neoplasms 158Pancreatic Neoplasms 151Leukemia, Myeloid, Acute 139Multiple Myeloma 130Uterine Cervical Neoplasms 127Recurrence 116Rectal Neoplasms 112Ovarian Neoplasms 105Neoplasm Metastasis 104Squamous Cell Carcinoma of Head and Neck 97Head and Neck Neoplasms 89Esophageal Neoplasms 85Triple Negative Breast Neoplasms 84Glioblastoma 80Small Cell Lung Carcinoma 79Endometrial Neoplasms 79Colonic Neoplasms 78Brain Neoplasms 78Melanoma 69Precursor Cell Lymphoblastic Leukemia-Lymphoma 66Hematologic Neoplasms 64Glioma 62Motor Activity 60

Interventions

pembrolizumab 2lenvatinib 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Endometrial Cancer × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡